EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	709	514/252.16.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/23 13:24
L2	2	pyrazolopyrimidinethione	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/23 13:30
L3	1	l1 and l2	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/23 13:25
S1	4	((SHUXIN) near2 (LI)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/23 13:21
S2	9	((JIANPING) near2 (REN)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:20
S3	1	((YANJIN) near2 (ZHAO)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:20
S4	1	((QIUJUN) near2 (LV)).INV.	US-PGPUB; USPAT; USOCR	OR	ON.	2007/10/22 11:20
S5	1	((JINHUA) near2 (GUO)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:43
S6	2	("6200782" "6350751").PN.	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:44
S7	1407	pyrazolopyrimidine\$	US-PGPUB; USPAT; USOCR	OR .	ON	2007/10/22 11:45
S8	1398	pyrazolopyrimidine	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:44
S9	14	S1 S2 S3 S4 S5 S6	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:44
S10	1	S7 and S9	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:44
S11	0	S8 and S9	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:44
S12	2	pyrazolopyrimidinethione\$	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:45

EAST Search History

S13	2	pyrazolopyrimidinethione	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:45
S14	1	S12 and S9	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:45
S15	1	S13 and S9	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/22 11:45
S16	. 0	"204152709"	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/23 10:25
S17	0	"2004152709"	US-PGPUB; USPAT; USOCR	OR	ON .	2007/10/23 10:25
S18	1	"20040152709"	US-PGPUB; USPAT; USOCR	OR	ON	2007/10/23 10:25

Page 2

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:02:47 ON 23 OCT 2007

=> file registry
COST IN U.S. DOLLARS

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:03:14 ON 23 OCT 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 OCT 2007 HIGHEST RN 951124-19-9 DICTIONARY FILE UPDATES: 21 OCT 2007 HIGHEST RN 951124-19-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading C:\Program Files\Stnexp\Queries\10 series\10583335\10583335b.str





chain nodes :
10 17 18 19 26 27 28 29 31
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 20 21 22 23 24 25
chain bonds :
2-11 4-10 7-28 9-27 13-17 16-26 17-18 17-19 17-20 23-29 26-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 7-28 8-9 9-27 13-17 16-26
17-18 17-19 17-20 20-21 20-25 21-22 22-23 23-24 23-29 24-25 26-31
exact bonds :

2-11

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16

G1:H,Ak,Cb

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS
29:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

T.1

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT * Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:03:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 89 TO ITERATE

100.0% PROCESSED

89 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

1214 TO 2346

PROJECTED ANSWERS:

9 TO 360

L2 9 SEA SSS SAM L1

=> d scan

L2 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Piperazine, 1-acetyl-4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-2,6-dimethyl-,
(2R,6S)-rel- [9CI]

MF C25 H34 N6 O5 S

Relative stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

FULL SEARCH INITIATED 10:04:03 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 1639 TO ITERATE

100.0% PROCESSED 1639 ITERATIONS

218 ANSWERS

SEARCH TIME: 00.00.01

L3 218 SEA SSS FUL L1

=> d scan

218 ANSWERS REGISTRY COPYRIGHT 2007 ACS ON STN INDEX NAME NOT YET ASSIGNED C22 H30 N6 O4 S . 1/2 C4 H6 O6

CM 2

Absolute stereochemistry.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

218 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl-, compd. with 5-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one (1:1) C22 H30 N6 O4 S . C4 H10 N3 O5 P

L3 218 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7H-Pyrazolo(4,3-d)pyrimidin-7-one, 1,6-dihydro-5-[2-methoxy-5-[[4-(1-methyl-1-l-piperazinyl)sulfonyl)phenyl]-1-methyl-3-propyl-MF C23 H32 No 04 S

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 218 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN a-L-Sorbofuranose, 6-deoxy-6-[4-{[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo!(4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-1-piperaxinyl]-1-0-dodecyl-2,3-0-(1-methylethylidene)-, hydrochloride (1:1)

MF C41 H64 N6 09 S . C1 H

Absolute stereochemistry.

PAGE 1-A

• HCl

PAGE 1-B

∠Pr-n

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 172.55 172.76

FILE 'CAPLUS' ENTERED AT 10:04:30 ON 23 OCT 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS, 1907 - 23 Oct 2007 VOL 147 ISS 18 FILE LAST UPDATED: 22 Oct 2007 (20071022/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13

1875 L3 L4

=> s 13 not pd>20031218 1875 L3 4864415 PD>20031218 (PD>20031218) 650 L3 NOT PD>20031218 L5

=> file registry

SINCE FILE COST IN U.S. DOLLARS TOTAL ENTRY SESSION 3.42 FULL ESTIMATED COST 176.18

FILE 'REGISTRY' ENTERED AT 10:06:07 ON 23 OCT 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

21 OCT 2007 HIGHEST RN 951124-19-9 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: 21 OCT 2007 HIGHEST RN 951124-19-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading C:\Program Files\Stnexp\Queries\10 series\10583335\10583335c.str

chain nodes:
10 17 18 19 26 27 28 29 31 32
ring nodes:

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 20 21 22 23 24 25

chain bonds :

2-11 4-10 7-28 9-27 13-17 16-26 17-18 17-19 17-20 22-32 23-29 26-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 7-28 8-9 9-27 13-17 16-26 17-18 17-19 17-20 20-21 20-25 21-22 22-23 22-32 23-24 23-29 24-25 26-31

exact bonds :

2-11

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16

G1:H,Ak,Cb

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 31:CLASS 32:CLASS

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 16

SAMPLE SEARCH INITIATED 10:06:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 89 TO ITERATE

100.0% PROCESSED 89 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1: PROJECTED ANSWERS:

1214 TO 2346 1 TO 80

L7 1 SEA SSS SAM L6

=> d scan

L7 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-acetyl-4-[(3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-2,6-dimethyl-,
(2R,68)-rel- (9CI)
MF C25 H34 N6 O5 S

Relative stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 16 full

FULL SEARCH INITIATED 10:07:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1639 TO ITERATE

100.0% PROCESSED 1639 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

L8

6 SEA SSS FUL L6

=> d scan

6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN Piperazine, 1-acetyl-4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-ethoxyphenyl]sulfonyl]-2,6-dimethyl-,(2R,65)-rel- [9CI)
C25 H34 N6 O5 S

Relative stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L8 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[4-ethoxy-3-(1-ethyl-4,7-dihydro-7-oxo-3-propyl-1Hpyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl]-3,5-dimethyl-,
(3R,SS)-rel(9CI)
MF C24 H34 N6 O4 S

Relative stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN Piperazinium, 4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-lH-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-1,1,2,6-tetramethyl-, (2R,68)-rel- (9CI) C25 H37 N6 O4 S

Relative stereochemistry.

L8 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
TH-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[5-[{3R,5S}-3,5-dimethyl-1-piperazinyl]sulfonyl]-2-ethoxyphenyl]-1,6-dihydro-1-methyl-3-propyl-,
FE C23 H32 N6 O4 S

Relative stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 172.55 348.73

FILE 'CAPLUS' ENTERED AT 10:07:26 ON 23 OCT 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Oct 2007 VOL 147 ISS 18 FILE LAST UPDATED: 22 Oct 2007 (20071022/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 18

L9 8 L8

=> d l9 1-8 ibib abs hitstr

L9 ANSWER 1 OF 8
ACCESSION NUMBER:

2007:828226 CAPLUS
Use of liquid chromatography-mass spectrometry and a chemical cleavage reaction for the structure elucidation of a new sildenafil analogue detected as an adulterant in an herbal dietary supplement
Reepmeyer, John C.; Woodruff, Jeffrey T.
Division of Pharmaceutical Analysis, US Food and Drug Administration, St. Louis, Mo. 63101, USA
Journal of Pharmaceutical and Blomedical Analysis (2007), 44(4), 887-893
CODEN: JPBADA; ISSN: 0731-7085
Elsevier B.V.
DOCUMENT TYPE:
Journal
LANGUAGE:
English
AB An herbal dietary supplement, marketed as a natural product for the enhancement of sexual function, was analyzed by HPLC with photodiode

and mass spectral detection and found to contain a compound related to

synthetic phosphodiesterase-5 (PDE-5) inhibitors. Based on UV spectra, mass spectra and direct infusion MSn, the structure of the compound was tentatively identified as a sildensfii analog in which the sulfonyl group had been replaced with an acetyl group. This new analog is similar to acetildensfii, a previously reported sildensfii analog, but differs in that it contains an N-He group where acetildenafil contains an N-Et

that it contains an error your more group.

The structure of the unknown was unequivocally established by chemical cleavage of the phenacylamine group of the mol. to generate N-methylpiperazine; other cleavage products matched those generated from acetildenafil. Since the new compound has one less CH2 group than acetildenafil, it was named nor-acetildenafil.

1T 496835-35-9

496835-35-y
RE: ANT (Analyte); ANST (Analytical study)
(use of liquid chromatog.-mass spectrometry and a chemical cleavage

(CA INDEX NAME)

Relative stereochemistry.

REFERENCE COUNT:

16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 2007:646673 CAPLUS DOCUMENT NUMBER: 147:125726 Medicine containing alidenafi 147:125726
Medicine containing aildenafil for treating sexual impotence
Liu, Baoshun
Peop. Rep. China
Faming Zhuanli Shenqing Gongkai Shuomingshu, 13pp.
CODEN: CNXXEV
Patent
Chinese
1

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1977846	A	20070613	CN 2005-10127647	20051206
DRIORITY ADDIN INFO .			CN 2005-10127647	20051206

AB The title medicine contains aildenafil 13-120 mg (0.3-18 weight), especially 30-120 mg (0.3-3 mg/kg body weight), 30-90 mg/kg (0.3-1.8 mg/kg body weight), and 30-60 mg (0.3-1.2 mg/kg body weight). The dosage form of

weight), and 30-60 mg (0.3-1.2 mg/kg body weight). The dosage form of the medicine can be tablet, capsule, powder, granule, crystal, solution, suspension, syrup, tincture, chewing formulation, nasal spray, nose drop, gel, cream, ointment, emulsion, etc.

IT 496835-35-9

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicine containing aildenafil for treating sexual impotence)

RN 496835-35-9 CAPLUS

CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[5-[[(3R,58)-3,5-dimethyl-1-piperazinyl]sulfonyl]-2-ethoxyphenyl]-1,6-dihydro-1-methyl-3-propyl-, rel
(CA INDEX NAME)

(CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 2007:422822 CAPLUS DOCUMENT NUMBER: 147:63259 Liquid chromatography tandem

Liquid chromatography tandem mass spectrometry assay to determine the pharmacokinetics of aildenafil in human plasma Wang, Jiang; Jiang, Yao; Wang, Yingwu; Zhao, Xia;

AUTHOR(S): Cui, .

CORPORATE SOURCE: Research Center for Drug Metabolism, College of Life Science, Jilin University, Changchun, 130023, Peop. Rep. China
SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2007), 44(1), 231-235
CODEN: JPBADA; ISSN: 0731-7085
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal LANGUAGE: English
AB A simple, sensitive and specific liquid chromatog./tandem mass
spectrometry
method for the quantitation of aildenafil, a new phosphodiesterase V inhibitor, in human plasma is presented. The analyte and internal standard,

inhibitor, in human plasma is presented. The analyte and internal standard, sildenafil, were extracted by a one-step liquid-liquid extraction in alkaline conditions and separated on a C18 column using ammonia:10mM ammonium acetate buffer:methanol (0.1:15:85, volume/volume/v) as the mobile phase. The detection by an API 4000 triple quadrupole mass spectrometer in multiple-reaction monitoring mode was completed within 2.5 min. The calibration curve exhibited a linear dynamic range of 0.05 - 100 ng/mL with a 10 pg/mL limit of detection. The intra- and inter-day precisions measured as relative standard deviation were within 8.04% and 5.72%, resp.

This method has been used in a pharmacokinetic study of aildenafil in healthy male volunteers each given an oral administration of one of the three dosages, 496835-35-9, Alldenafil RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study) [liquid chromatog, tandem mass spectrometry assay to determine the pharmacokinetics of aildenafil in human plasma) 496835-35-9 CAPLUS 7H-Pytezolo(4,3-d)pyrimidin-7-one, 5-[5-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]sulfonyl]-2-ethoxyphenyl]-1,6-dihydro-1-methyl-3-propyl-,

(CA INDEX NAME)

Relative stereochemistry.

ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L9 ANSWER 5 OF 8
ACCESSION NUMBER:
DOCUMENT NUMBER:
143:97390

11TLE:
1NVENTOR(S):
1NVENTOR(S):
2005:570896 CAPLUS
143:97390

Preparation of pyrazolopyrimidinethione derivatives
for treatment of impotence
for treatment of pyrazolopyrimidinethione derivatives
for treatment of impotence
for t

PATENT NO.					KIND DATE				APPL		DATE							
													-					
	WO	2005	0588	99		A1		2005	0630		WO 2	004-	CN13	12		2	0041	118
		W:	AE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
			CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE.	GH.	GM,	HR.	HU,	ID,	IL.	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ.	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MCK,	MZ,	NA,	NI,
			NO.	NZ,	OM,	PG.	PH,	PL.	PT,	RO,	RU,	sc.	SD,	SE.	SG,	SK,	SL,	SY,
			TJ.	TM.	TN,	TR.	TT,	TZ,	UA.	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:						MW.										
			AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	cz,	DE,	DK,
								GR,										
			SE.	SI.	SK.	TR.	BF.	BJ.	CF.	CG.	CI.	CM.	GA.	GN.	GO.	GW.	ML.	MR.
			NE.	SN.	TD.	TG												
	CN	1629	163			А		2005	0622		CN 2	003-	1011	8481		2	0031	218
	EP	1695	976			A1		2006	0830		EP 2	004-	7973	43		2	0041	118
		R:	AT.	BE.	CH.	DE.	DK.	ES,	FR.	GB.	GR,	IT.	LI,	LU,	NL,	SE,	MC,	PT,
			IE.	SI.	FI.	RO.	CY.	TR.	BG.	cz.	EE.	HU.	PL,	SK,	IS			
	IN	2006	MNOO	737	-	A.		2007	0330		IN 2	006-	MN73	7		2	0060	623
		2007																
PRIO		APP									CN 2							
											_	-				_		-

WO 2004-CN1312

OTHER SOURCE(S): CASREACT 143:97390; MARPAT 143:97390

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:345344 CAPLUS
DOCUMENT NUMBER: 147:39501
TITLE: Structure elucidation of a novel analogue of
sildenafil detected as an adulterant in an herbal
dietary supplement
AUTHOR(S): Reepmeyer, John C.; Woodruff, Jeffrey T.; 'Avignon,

Andre
Division of Pharmaceutical Analysis, US Food and Drug
Administration, St. Louis, MO, 63101, USA
Journal of Pharmaceutical and Biomedical Analysis
(2007), 43(5), 1615-1621
CODEN: JPRADA; ISSN: 0731-7085
Elsevier B.V. CORPORATE SOURCE:

SOURCE:

PUBLISHER: DOCUMENT TYPE: LANGUAGE:

Journal

UNGE: English
A new analog of sildenefil was detected in an herbal dietary supplement, which was sold over the internet and promoted as a product for the enhancement of sexual performance. The structure of the compound was established using LC-MS, UV spectroscopy, MS-MS, and NMR. In addition,

compound was cleaved at its sulfonamide S-N bond yielding a sulfonic acid and an amine, which were independently characterized using Lc-MS, Gc-MS, and derivatization. The compound, named methisosildenafil, is a novel synthetic analog of sildenafil in which the N-methylpiperazine moiety has been replaced with 2,6-dimethylpiperazine.
496835-35-9, Methisosildenafil
RL: ANT (Analyte): ANST (Analytical study)
(structure elucidation of a novel analog of sildenafil detected as an adulterant in an herbal dietery supplement)
496835-35-9 CAPLUS
71-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[5-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]sulfonyl]-2-ethoxyphenyl]-1,6-dihydro-1-methyl-3-propyl-,

(CA INDEX NAME)

Relative stereochemistry.

THERE ARE 15 CITED REFERENCES AVAILABLE FOR REFERENCE COUNT: THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

11

AB Title compds. represented by the formula I (wherein R1-R3 = independently ((cyclo)alkoxy)alkyl, alkenyl or aryl: R4 = alkyl, alkenyl, (cyclo)alkoxy, aryl: R5 = H, alkyl, alkenyl, (cyclo)alkoxy, aryl: R6 = H, (cyclo)alkyl, alkenyl, alkylcarbonyl: and pharmaceutically acceptable salts or solvates thereof) were prepared for treatment of impotence. For example, II was given in a multi-step synthesis starting from 4-amino-1-athyl-3-propylpyrazole-5-carboxamide. I showed enhanced erectile response in rats

similar to that of Sildenafil. Thus, I and their pharmaceutical compnsare useful for the treatment of impotence and sexlessness, having high selectivity over PDE V, long action time, less side reactions, and no

W 20041118

side

effects of blood pressure decreasing and heart rate increasing.

856190-55-1P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidinethione derivs. for treatment of impotence)

RN 856190-55-1 CAPLUS

RN Piperazine, 1-[4-ethoxy-3-(1-ethyl-4,7-dihydro-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]phenyl[sulfonyl]-3,5-dimethyl-,

(3R,53)-rel
(9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE REFERENCE COUNT:

FORMAT

ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) piperazinyl]sulfonyl]-2-ethoxyphenyl]-1,6-dihydro-1-methyl-3-propyl-, (CA INDEX NAME)

Relative stereochemistry.

852615-88-4P 852615-89-5P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological atudy); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperazine derivs. for treating

Relative stereochemistry.

852615-89-5 CAPLUS
Piperazinium, 4-[[3-[4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-1,1,2,6-tetramethyl-,
[2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:476529 CAPLUS
DOCUMENT NUMBER: 143:7736
TITLE: Preparation of piperazine derivatives for treating

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

impotence
Liu, Baoshun; Wang, Maotian
Peop. Rep. China
Faming Zhuanli Shenqing Gongkai Shuomingshu, No pp.
Givan
CODEN: CNXXEV

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: Patent Chinese

DATE PATENT NO. KIND DATE APPLICATION NO. CN 1517349 PRIORITY APPLN. INFO.: 20040804 CN 2003-100488 CN 2003-100488 Α

OTHER SOURCE(S):

CASREACT 143:7736; MARPAT 143:7736

The title compds. I [wherein R1 and R2 = independently alky1; R3 = acyl

dimethyl] or pharmaceutically acceptable salts or isomers thereof are prepared for the treatment of impotence. For example, the compound II

prepared II showed good result in treating impotence in rat. 496835-35-9P RE: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of piperazine derivs. for treating

| (14 by Section 14 for 15 for 16 for

(Continued)

ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1009838 CAPLUS
DOCUMENT NUMBER: 142:392422
Preparation of fused ring aromatic compounds for treatment of sexual disorders
Lu, Derang: Li, Zhihai
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Paning Zhuenli Shenqing Gongkai Shuomingshu, 15 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: Chinese 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1472210 PRIORITY APPLN. INFO.:	A	20040204	CN 2002-138880 CN 2002-138880	20020802 20020802

OTHER SOURCE(S):

MARPAT 142:392422

AB The title compds. I=N+R7R8R9R10 and II=NR7R8R9R10 (wherein R1 = H, alkyl, haloalkyl, or cycloalkyl; R2 = H, (un)substituted alkyl, haloalkyl,

alkyl, or cycloalkyl; R3 = H, (un)substituted alkyl, haloalkyl, cycloalkyl, alkenyl, or alkynyl; R4 = (un)substituted NHZ or piperazinyl; R7, - R10 = independently aryl or alkyl; X = CH or N] are prepared for the treatment

οf sexual disorders. For example, the compound III=N+Me3(CH2CH2OH) was prepared in a two-step synthesis in good yield. The title compds. showed

ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) strong effect on sexual disorders in rat.

IT 849915-00-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use): BIOL (Biological study); PREP (Preparation): USES (Uses)
(preparation of fused ring aromatic compds. for treatment of sexual disorders)
RN 849915-00-0 CAPLUS
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with rel-(3R,SS)-1-[13-44,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-3,5-dimethylpiperazine (1:1) (9CI) (CA INDEX NAME)

CM

CRN 849914-99-4 CMF C23 H31 N6 O4 S

Relative stereochemistry.

2

CRN 62-49-7 CMF C5 H14 N O

ме3+N- CH2- CH2- ОН

IT 496835-35-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused ring aromatic compds. for treatment of sexual disorders)
RN 496835-35-9 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[5-[{(3R,5S)-3,5-dimethyl-1-piperazinyl]sulfonyl]-2-ethoxyphenyl]-1,6-dihydro-1-methyl-3-propyl-, rel-

(CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
138:153550
Preparation of pyrazolopyrimidine derivatives for treatment of impotence
LLu, Baosahun
PATEMT ASSIGNEE(S):
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATEMT INFORMATION:

COPRIGHT 2007 ACS on STN
ACPLUS
PREPARATION OF PATEMT INFORMATION:

2003:154433 CAPLUS
Preparation of pyrazolopyrimidine derivatives for treatment of impotence
LLu, Baosahun
Pacper InfoRmation:
LLu, Baosahun
Patper InfoRmation:
LLu, Baosahun
Patper InfoRmation:
LLu
Patper InfoRmation:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	PATENT NO.				KIND DATE			APPLICATION NO.						DATE					
								WO 2002-CN433											
								AU,											
								DM,											
								ıs.											
								MG,											
								SG,											
								ZA,									•		
		RW:						MZ,				TZ.	UG.	ZM.	ZW.	AT.	BE.	CH.	
								FR,											
			00	0.7	CE	cc.	CT.	CM	GB.	CN	GO.	CM.	М7.	MD	NF	RN:	TD	TC	
	CN	1393 1127	444			A		2003	0129		CN 2	002-	1001	98		2	0020	118	
	CN	1127	506			В		2003	1112										
	ΑU	2002	3237	74		A1		2003	0303		AU 2	002-	3237	74		2	0020	621	
	EΡ	2002	522			A1		2004	0324		EP 2	002~	7541	39		2	0020	621	
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR							
	BR	2002 2005 5305 2279 1053 2004 6960 2003	0110	25		A		2004	1019		BR 2	002-	1102	5		2	0020	621	
	JΡ	2005	5003	91		T		2005	0106		JP 2	003-	5212	35		2	0020	621	
	NZ	5305	48			А		2005	0429	- 1	NZ 2	002~	5305	48		2	0020	621	
	Rυ	2279	433			C2		2006	0710		RU 2	004-	1025	13		2	0020	621	
	HК	1053	108			A1		2004	0402		HK 2	003-	1053	10		2	0030	723	
	US	2004	1527	09		A1		2004	0805		US 2	003-	7367	32		2	0031	216	
	US	6960	592			B2		2005	1101										
	ΜX	2003	PA11	929		А		2005	0307		MX 2	003-	PA11	929		2	0031	218	
	IN	2003	DN02	254		А		2006	0120		IN 2	003~	DN22	54		2	0031	224	
	ZΑ	2004	0006	92		А		2004	1014		ZA 2	004-	692			2	0040	128	
PRIO	RIT	2003 2004 (APP	LN.	INFO	. :						CN 2	001-	1296	91		A 2	0010	629	
											CN 2	002-	1001	98		A 2	0020	110	
										1	WO 2	002-	CN43	3	1	₩ 2	0020	621	

OTHER SOURCE(S):

CASREACT 138:153550; MARPAT 138:153550

ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

Title compound I $\{R1, R2 = alkyl\}$ and their pharmaceutically acceptable salts or their configuration isomers., useful for treatment of impotence, are prepared Thus, I $\{R1 = R2 = Me\}$ $\{II\}$ was prepared in several steps

are prepared Thus, I (R1 = R2 = Me) (II) was prepared in several steps

2-ethoxybenzoic acid. II showed enhanced erectile response in rats
similar to that of sildenafil.

17 496835-33-9P
RL: ADV (Adverse effect, including toxicity); IMF (Industrial
manufacture); PAC (Pharmacological activity); SPN (Synthetic
preparation);
THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of pyrazolopyrimidine derivs. for treatment of impotence)
RN 496835-33-9 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[5-[[(3R,5s)-3,5-dimethy]-1piperazinyl]sulfonyl]-2-ethoxyphenyl]-1,6-dihydro-1-methyl-3-propyl-,
rel(CA INDEX NAME)

(CA INDEX NAME)

Relative stereochemistry.

3

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> log hold SINCE FILE COST IN U.S. DOLLARS TOTAL ENTRY SESSION 45.45 394.18 FULL ESTIMATED COST TOTAL DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE SESSION ENTRY CA SUBSCRIBER PRICE -6.24 -6.24

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:11:40 ON 23 OCT 2007